<DOC>
	<DOCNO>NCT01189396</DOCNO>
	<brief_summary>The main objective evaluate bronchodilatory efficacy , safety pharmacokinetic profile A006 , comparison active control , Proventil®-HFA MDI , placebo control DPI , escalate cumulative-doses 1,440 mcg , eight ( 8 ) time propose clinical dose .</brief_summary>
	<brief_title>Escalating Cumulative-Dose Study Pharmacokinetics ( PK ) , Pharmacodynamics ( PD ) Safety A006</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Bronchial Spasm</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<criteria>Body weight ≥ 50 kg men ≥ 45 kg woman , BMI within range 18.5 30.0 kg/m2 inclusive ; Sitting blood pressure ≤ 135/90 mmHg ; Demonstrating negative alcohol/drug screen test ; Demonstrating negative HIV , HBsAg HCVAb screen test ; With mildtomoderate persistent asthma least 6 month prior Screening , use inhaled βagonist ( ) asthma control ; Demonstrating Mean Screening Baseline FEV1 50.0 85.0 % predict normal ; Demonstrating ≥ 15.0 % Airway Reversibility FEV1 within 30 ( ±5 ) min inhale 2 actuation Proventil® MDI ; Demonstrating Peak Inspiratory Flow Rate within 80150 L/min ; Demonstrating proficiency use DPI MDI training ; Females childbearing potential must nonpregnant , nonlactating , practice clinically acceptable form birth control ; Having properly consent participate trial . Smoking history ≥ 10 packyears , smoke within 6 month prior Screening ; Upper respiratory tract infection within 2 wk , low respiratory tract infection within 4 wk ; Asthma exacerbation require emergency care hospitalize treatment , within 4 wk prior ; Any current recent respiratory condition might significantly affect pharmacodynamic response study drug , besides asthma ; Concurrent clinically significant cardiovascular , hematological , renal , neurologic , hepatic , endocrine , psychiatric , malignancy , illness could impact conduct , safety evaluation study ; Known intolerance hypersensitivity ingredient study drug DPI Proventil® MDI ; Use prohibit drug failure observe drug washout restriction ; Having clinical drug/device study last 30 day ; Having donate blood within last 30 day prior Screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>asthma</keyword>
	<keyword>bronchospasm</keyword>
	<keyword>COPD</keyword>
	<keyword>reversibility</keyword>
	<keyword>efficacy</keyword>
</DOC>